Item 8.01 Other Events.

On January 21, 2021, Aquestive Therapeutics, Inc. (the "Company") and Mitsubishi Tanabe Pharma America, Inc. issued a joint press release announcing the Company's exclusive license to Mitsubishi Tanabe Pharma Holdings America, Inc. for the commercialization in the United States of Exservan™ (riluzole), an oral film formulation of riluzole for the treatment of amyotrophic lateral sclerosis (ALS). A copy of such press release is attached as Exhibit 99.1 to this report and incorporated into this Item 8.01 by reference.

Item 9.01 Financial Statements and Exhibits.





(d) Exhibits.



Exhibit Number   Description

  99.1           Press Release, dated January 21, 2021.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses